Dr. Mutch on Frontline Treatment in Endometrial Cancer

David Mutch, MD
Published: Friday, Mar 16, 2018



David Mutch, MD, Ira C. and Judith Gall professor, vice chair of obstetrics and gynecology, chief, Division of Gynecologic Oncology, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses frontline treatment for patients with endometrial cancer.

In patients who have high-risk endometrial cancer, Mutch argues that based on GOG-209, which randomized patients to cisplatin, paclitaxel, and doxorubicin versus carboplatin and paclitaxel, the survival is the same in both arms. Toxicity is greater in the triplet therapy group; therefore, standard therapy for upfront treatment would be carboplatin and paclitaxel in the high-risk patients.

However, patients need to be monitored for a cuff recurrence. Cuff recurrences, if monitored carefully, have a cure rate of 100%. Then, radiation therapy is certainly indicated.
 
SELECTED
LANGUAGE


David Mutch, MD, Ira C. and Judith Gall professor, vice chair of obstetrics and gynecology, chief, Division of Gynecologic Oncology, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses frontline treatment for patients with endometrial cancer.

In patients who have high-risk endometrial cancer, Mutch argues that based on GOG-209, which randomized patients to cisplatin, paclitaxel, and doxorubicin versus carboplatin and paclitaxel, the survival is the same in both arms. Toxicity is greater in the triplet therapy group; therefore, standard therapy for upfront treatment would be carboplatin and paclitaxel in the high-risk patients.

However, patients need to be monitored for a cuff recurrence. Cuff recurrences, if monitored carefully, have a cure rate of 100%. Then, radiation therapy is certainly indicated.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x